{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:38:59Z","timestamp":1792643939588,"version":"4.5.0"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T00:00:00Z","timestamp":1550016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s10157-019-01700-1","type":"journal-article","created":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T20:34:58Z","timestamp":1550003698000},"page":"577-588","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["New strategies and perspectives on managing IgA nephropathy"],"prefix":"10.1007","volume":"23","author":[{"given":"Haresh","family":"Selvaskandan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chee Kay","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Muto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9063-7229","authenticated-orcid":false,"given":"Jonathan","family":"Barratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,13]]},"reference":[{"issue":"8","key":"1700_CR1","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nrneph.2014.92","volume":"10","author":"ISD Roberts","year":"2014","unstructured":"Roberts ISD. Pathology of IgA nephropathy. Nat Rev Nephrol. 2014;10(8):445\u201354.","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"1700_CR2","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/j.1744-9987.2006.00440.x","volume":"10","author":"S Nakai","year":"2006","unstructured":"Nakai S, Wada A, Kitaoka T, Shinzato T, Nagura Y, Kikuchi K, et al. An overview of regular dialysis treatment in Japan (as of 31 December 2004). Ther Apher Dial. 2006;10(6):476\u201397.","journal-title":"Ther Apher Dial"},{"issue":"9","key":"1700_CR3","first-page":"694","volume":"74","author":"J Berger","year":"1968","unstructured":"Berger J, Hinglais N. Intercapillary deposits of IgA-IgG. J Urol Nephrol (Paris). 1968;74(9):694\u20135.","journal-title":"J Urol Nephrol (Paris)"},{"key":"1700_CR4","doi-asserted-by":"crossref","unstructured":"Hwang S, Tsai J, Chen H. Epidemiology, impact and preventive care of chronic kidney disease in Taiwan. Nephrology (Carlton). 2010;15Suppl 2:3\u20139.","DOI":"10.1111\/j.1440-1797.2010.01304.x"},{"issue":"12","key":"1700_CR5","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/nep.12538","volume":"20","author":"CL Chembo","year":"2015","unstructured":"Chembo CL, Marshall MR, Williams LC, Walker RJ, Lynn KL, Irvine J, et al. Long-term outcomes for primary glomerulonephritis: New Zealand Glomerulonephritis Study. Nephrology (Carlton). 2015;20(12):899\u2013907.","journal-title":"Nephrology (Carlton)"},{"issue":"18","key":"1700_CR6","doi-asserted-by":"publisher","first-page":"e3633","DOI":"10.1097\/MD.0000000000003633","volume":"95","author":"S Murugapandian","year":"2016","unstructured":"Murugapandian S, Mansour I, Hudeeb M, Hamed K, Hammode E, Bijin B, et al. Epidemiology of glomerular disease in Southern Arizona: review of 10-year renal biopsy data. Medicine. 2016;95(18):e3633.","journal-title":"Medicine"},{"issue":"10","key":"1700_CR7","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s00011-016-0962-x","volume":"65","author":"RCG Fabiano","year":"2016","unstructured":"Fabiano RCG, Pinheiro SVB, Sim\u00f5es E, Silva A. Immunoglobulin A nephropathy: a pathophysiology view. Inflamm Res. 2016;65(10):757\u201370.","journal-title":"Inflamm Res"},{"issue":"10","key":"1700_CR8","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1681\/ASN.2011050464","volume":"22","author":"H Suzuki","year":"2011","unstructured":"Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol. 2011;22(10):1795\u2013803.","journal-title":"J Am Soc Nephrol"},{"issue":"25","key":"1700_CR9","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1056\/NEJMra1206793","volume":"368","author":"RJ Wyatt","year":"2013","unstructured":"Wyatt RJ, Julian BA. IgA Nephropathy. N Engl J Med. 2013;368(25):2402\u201314.","journal-title":"N Engl J Med"},{"issue":"3","key":"1700_CR10","first-page":"CD003962","volume":"16","author":"S Reid","year":"2011","unstructured":"Reid S, Cawthon PM, Craig JC, Samuels JA, Molony DA, Strippoli GF. Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev 2011;16(3):CD003962.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"1700_CR11","doi-asserted-by":"publisher","first-page":"205","DOI":"10.12968\/jokc.2017.2.4.205","volume":"2","author":"H Selvaskandan","year":"2017","unstructured":"Selvaskandan H, Dillon M, Barratt J. IgA nephropathy: driving innovation with a rare renal disease registry. J Kidney Care 2017;2(4):205\u201311.","journal-title":"J Kidney Care"},{"issue":"3","key":"1700_CR12","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.kint.2017.10.028","volume":"93","author":"J Floege","year":"2018","unstructured":"Floege J. IgA nephropathy: toward more specific diagnosis (and rescue of snails). Kidney Int. 2018;93(3):542\u20134.","journal-title":"Kidney Int"},{"key":"1700_CR13","first-page":"56","volume":"08","author":"H Suzuki","year":"2018","unstructured":"Suzuki H. Biomarkers for IgA nephropathy on the basis of multi-hit pathogenesis. Clin Exp Nephrol. 2018;08:56","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"1700_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/ckj\/sfx096","volume":"11","author":"H Selvaskandan","year":"2018","unstructured":"Selvaskandan H, Pawluczyk I, Barratt J. MicroRNAs: a new avenue to understand, investigate and treat immunoglobulin A nephropathy? Clin Kidney J. 2018;11(1):29\u201337.","journal-title":"Clin Kidney J"},{"issue":"5","key":"1700_CR15","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/ki.2009.168","volume":"76","author":"ISD Roberts","year":"2009","unstructured":"Roberts ISD, Cook HT, Troyanov S, Alpers CE, Amore A, Barratt J, et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009;76(5):546\u201356.","journal-title":"Kidney Int"},{"issue":"2","key":"1700_CR16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/kisup.2012.23","volume":"2","author":"KDIGO","year":"2012","unstructured":"KDIGO. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012;2(2):209\u201317.","journal-title":"Kidney Int Suppl"},{"issue":"6","key":"1700_CR17","doi-asserted-by":"publisher","first-page":"e1002765","DOI":"10.1371\/journal.pgen.1002765","volume":"8","author":"K Kiryluk","year":"2012","unstructured":"Kiryluk K, Li Y, Sanna-Cherchi S, Rohanizadegan M, Suzuki H, Eitner F, et al. Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet. 2012;8(6):e1002765.","journal-title":"PLoS Genet"},{"key":"1700_CR18","unstructured":"The Special Study Group of the Progressive Renal Dysfunction Research Group of the Ministry of. Health Labour and Welfare. Evidence-based clinical practice guidelines for IgA nephropathy 2017. Tokyo-igakusha, Tokyo 2017."},{"issue":"Suppl 1","key":"1700_CR19","first-page":"3","volume":"15","author":"E Koulouridis","year":"2011","unstructured":"Koulouridis E, Koulouridis I. Is the dietary protein restriction achievable in chronic kidney disease? The impact upon quality of life and the dialysis delay. Hippokratia 2011;15(Suppl 1):3\u20137.","journal-title":"Hippokratia"},{"issue":"2","key":"1700_CR20","first-page":"CD001892","volume":"19","author":"D Fouque","year":"2006","unstructured":"Fouque D, Laville M, Boissel JP. Low protein diets for chronic kidney disease in non diabetic adults. Cochrane Database Syst Rev. 2006;19,(2):CD001892.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1700_CR21","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1161\/01.HYP.38.1.81","volume":"38","author":"Y Konishi","year":"2001","unstructured":"Konishi Y, Okada N, Okamura M, Morikawa T, Okumura M, Yoshioka K, et al. Sodium sensitivity of blood pressure appearing before hypertension and related to histological damage in immunoglobulin a nephropathy. Hypertension. 2001;38(1):81\u20135.","journal-title":"Hypertension"},{"issue":"4","key":"1700_CR22","doi-asserted-by":"publisher","first-page":"274","DOI":"10.5414\/CNP72274","volume":"72","author":"T Suzuki","year":"2009","unstructured":"Suzuki T, Miyazaki Y, Shimizu A, Ito Y, Okonogi H, Ogura M, et al. Sodium-sensitive variability of the antiproteinuric efficacy of RAS inhibitors in outpatients with IgA nephropathy. Clin Nephrol. 2009;72(4):274\u201385.","journal-title":"Clin Nephrol"},{"issue":"Suppl 4","key":"1700_CR23","first-page":"98","volume":"28","author":"D Bolignano","year":"2013","unstructured":"Bolignano D, Zoccali C. Effects of weight loss on renal function in obese CKD patients: a systematic review. Nephrol Dial Transplant. 2013;28(Suppl 4):98.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"1700_CR24","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1111\/j.1523-1755.2004.00582.x","volume":"65","author":"K Iseki","year":"2004","unstructured":"Iseki K, Ikemiya Y, Kinjo K, Inoue T, Iseki C, Takishita S. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int. 2004;65(5):1870\u20136.","journal-title":"Kidney Int"},{"issue":"1","key":"1700_CR25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.7326\/0003-4819-144-1-200601030-00006","volume":"144","author":"C Hsu","year":"2006","unstructured":"Hsu C, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144(1):21\u20138.","journal-title":"Ann Intern Med"},{"issue":"9","key":"1700_CR26","doi-asserted-by":"publisher","first-page":"e0162044","DOI":"10.1371\/journal.pone.0162044","volume":"11","author":"Y Ouyang","year":"2016","unstructured":"Ouyang Y, Xie J, Yang M, Zhang X, Ren H, Wang W, et al. Underweight is an independent risk factor for renal function deterioration in patients with IgA nephropathy. PLoS One. 2016;11(9):e0162044.","journal-title":"PLoS One"},{"issue":"5","key":"1700_CR27","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/jcla.21778","volume":"29","author":"M Shimamoto","year":"2015","unstructured":"Shimamoto M, Ohsawa I, Suzuki H, Hisada A, Nagamachi S, Honda D, et al. Impact of Body Mass Index on progression of IgA nephropathy among Japanese patients. J Clin Lab Anal. 2015;29(5):353\u201360.","journal-title":"J Clin Lab Anal"},{"issue":"2","key":"1700_CR28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1159\/000213084","volume":"112","author":"M Tanaka","year":"2009","unstructured":"Tanaka M, Yamada S, Iwasaki Y, Sugishita T, Yonemoto S, Tsukamoto T, et al. Impact of obesity on IgA nephropathy: comparative ultrastructural study between obese and non-obese patients. Nephron Clin Pract. 2009;112(2):71.","journal-title":"Nephron Clin Pract"},{"key":"1700_CR29","first-page":"90","volume":"157","author":"M Tanaka","year":"2007","unstructured":"Tanaka M, Tsujii T, Komiya T, Iwasaki Y, Sugishita T, Yonemoto S, et al. Clinicopathological influence of obesity in IgA nephropathy: comparative study of 74 patients. Contrib Nephrol. 2007;157:90\u20133.","journal-title":"Contrib Nephrol"},{"issue":"4","key":"1700_CR30","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/S0272-6386(01)80120-7","volume":"37","author":"F Bonnet","year":"2001","unstructured":"Bonnet F, Deprele C, Sassolas A, Moulin P, Alamartine E, Berthez\u00e8ne F, et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. Am J Kidney Dis. 2001;37(4):720\u20137.","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 4","key":"1700_CR31","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/ndt\/gft286","volume":"28","author":"F Berthoux","year":"2013","unstructured":"Berthoux F, Mariat C, Maillard N. Overweight\/obesity revisited as a predictive risk factor in primary IgA nephropathy. Nephrol Dial Transplant. 2013;28(Suppl 4):166.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"1700_CR32","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1053\/j.jrn.2014.01.016","volume":"24","author":"P Kittiskulnam","year":"2014","unstructured":"Kittiskulnam P, Kanjanabuch T, Tangmanjitjaroen K, Chancharoenthana W, Praditpornsilpa K, Eiam-Ong S. The beneficial effects of weight reduction in overweight patients with chronic proteinuric immunoglobulin a nephropathy: a randomized controlled trial. J Ren Nutr. 2014;24(3):200\u20137","journal-title":"J Ren Nutr"},{"issue":"1","key":"1700_CR33","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3349\/ymj.2016.57.1.209","volume":"57","author":"YJ Cha","year":"2016","unstructured":"Cha YJ, Lim BJ, Kim BS, Kim Y, Yoo TH, Han SH, et al. Smoking-related renal histologic injury in IgA nephropathy patients. Yonsei Med J. 2016;57(1):209\u201316.","journal-title":"Yonsei Med J"},{"issue":"2","key":"1700_CR34","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1053\/j.ajkd.2010.02.351","volume":"56","author":"R Yamamoto","year":"2010","unstructured":"Yamamoto R, Nagasawa Y, Shoji T, Iwatani H, Hamano T, Kawada N, et al. Cigarette smoking and progression of IgA nephropathy. Am J Kidney Dis. 2010;56(2):313\u201324.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"1700_CR35","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1046\/j.1523-1755.1998.00067.x","volume":"54","author":"SR Orth","year":"1998","unstructured":"Orth SR, St\u00f6ckmann A, Conradt C, Ritz E, Ferro M, Kreusser W, et al. Smoking as a risk factor for end-stage renal failure in men with primary renal disease. Kidney Int. 1998;54(3):926\u201331.","journal-title":"Kidney Int"},{"issue":"1","key":"1700_CR36","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1093\/ndt\/gfn454","volume":"24","author":"PM Ferraro","year":"2009","unstructured":"Ferraro PM, Ferraccioli GF, Gambaro G, Fulignati P, Costanzi S. Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial. Nephrol Dial Transplant. 2009;24(1):156\u201360.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"1700_CR37","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1081\/JDI-200026763","volume":"26","author":"E Alexopoulos","year":"2004","unstructured":"Alexopoulos E, Stangou M, Pantzaki A, Kirmizis D, Memmos D. Treatment of severe IgA nephropathy with omega-3 fatty acids: the effect of a \u201cvery low dose\u201d regimen. Ren Fail. 2004;26(4):453\u20139.","journal-title":"Ren Fail"},{"issue":"18","key":"1700_CR38","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1056\/NEJM199411033311804","volume":"331","author":"JV Donadio","year":"1994","unstructured":"Donadio JV, Bergstralh EJ, Offord KP, Spencer DC, Holley KE. A controlled trial of fish oil in IgA nephropathy. Mayo nephrology collaborative group. N Engl J Med. 1994;331(18):1194\u20139.","journal-title":"N Engl J Med"},{"issue":"4","key":"1700_CR39","first-page":"183","volume":"41","author":"EE Pettersson","year":"1994","unstructured":"Pettersson EE, Rekola S, Berglund L, Sundqvist KG, Angelin B, Diczfalusy U, et al. Treatment of IgA nephropathy with omega-3-polyunsaturated fatty acids: a prospective, double-blind, randomized study. Clin Nephrol. 1994;41(4):183\u201390.","journal-title":"Clin Nephrol"},{"issue":"6","key":"1700_CR40","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1681\/ASN.2006040347","volume":"18","author":"R Coppo","year":"2007","unstructured":"Coppo R, Peruzzi L, Amore A, Piccoli A, Cochat P, Stone R, et al. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol. 2007;18(6):1880\u20138.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"1700_CR41","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1053\/j.ajkd.2006.01.017","volume":"47","author":"PK Li","year":"2006","unstructured":"Li PK, Leung CB, Chow KM, Cheng YL, Fung SK, Mak SK, et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis. 2006;47(5):751\u201360.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"1700_CR42","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1097\/01.ASN.0000068460.37369.DC","volume":"14","author":"M Praga","year":"2003","unstructured":"Praga M, Guti\u00e9rrez E, Gonz\u00e1lez E, Morales E, Hern\u00e1ndez E. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol. 2003;14(6):1578\u201383.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"1700_CR43","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/j.1742-1241.2009.02038.x","volume":"63","author":"J Cheng","year":"2009","unstructured":"Cheng J, Zhang W, Zhang XH, He Q, Tao XJ, Chen JH. ACEI\/ARB therapy for IgA nephropathy: a meta analysis of randomised controlled trials. Int J Clin Pract. 2009;63(6):880\u20138.","journal-title":"Int J Clin Pract"},{"issue":"23","key":"1700_CR44","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","volume":"373","author":"T Rauen","year":"2015","unstructured":"Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B, et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med. 2015;373(23):2225.","journal-title":"N Engl J Med"},{"issue":"10","key":"1700_CR45","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1111\/j.1742-1241.2012.02970.x","volume":"66","author":"J Cheng","year":"2012","unstructured":"Cheng J, Zhang X, Tian J, Li Q, Chen J. Combination therapy an ACE inhibitor and an angiotensin receptor blocker for IgA nephropathy: a meta-analysis. Int J Clin Pract. 2012;66(10):917\u201323.","journal-title":"Int J Clin Pract"},{"issue":"9638","key":"1700_CR46","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","volume":"372","author":"JFE Mann","year":"2008","unstructured":"Mann JFE, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547\u201353.","journal-title":"Lancet"},{"key":"1700_CR47","first-page":"60","volume":"72","author":"J Novak","year":"2011","unstructured":"Novak J, Moldoveanu Z, Julian BA, Raska M, Wyatt RJ, Suzuki Y, et al. Aberrant glycosylation of IgA1 and anti-glycan antibodies in IgA nephropathy: role of mucosal immune system. Adv Otorhinolaryngol. 2011;72:60\u20133.","journal-title":"Adv Otorhinolaryngol"},{"issue":"2","key":"1700_CR48","doi-asserted-by":"publisher","first-page":"e89707","DOI":"10.1371\/journal.pone.0089707","volume":"9","author":"J Nakata","year":"2014","unstructured":"Nakata J, Suzuki Y, Suzuki H, Sato D, Kano T, Yanagawa H, et al. Changes in nephritogenic serum galactose-deficient IgA1 in IgA nephropathy following tonsillectomy and steroid therapy. PLoS One. 2014;9(2):e89707.","journal-title":"PLoS One"},{"issue":"3","key":"1700_CR49","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/S0272-6386(03)00743-1","volume":"42","author":"A Horie","year":"2003","unstructured":"Horie A, Hiki Y, Odani H, Yasuda Y, Takahashi M, Kato M, et al. IgA1 molecules produced by tonsillar lymphocytes are under-O-glycosylated in IgA nephropathy. Am J Kidney Dis. 2003;42(3):486\u201396.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"1700_CR50","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1093\/ndt\/gfg108","volume":"18","author":"A Itoh","year":"2003","unstructured":"Itoh A, Iwase H, Takatani T, Nakamura I, Hayashi M, Oba K, et al. Tonsillar IgA1 as a possible source of hypoglycosylated IgA1 in the serum of IgA nephropathy patients. Nephrol Dial Transplant. 2003;18(6):1108\u201314.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"1700_CR51","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.2215\/CJN.00310108","volume":"3","author":"H Komatsu","year":"2008","unstructured":"Komatsu H, Fujimoto S, Hara S, Sato Y, Yamada K, Kitamura K. Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: a controlled study. Clin J Am Soc Nephrol. 2008;3(5):1301\u20137.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"1700_CR52","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1046\/j.1523-1755.2003.00935.x","volume":"63","author":"Y Xie","year":"2003","unstructured":"Xie Y, Nishi S, Ueno M, Imai N, Sakatsume M, Narita I, et al. The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. Kidney Int. 2003;63(5):1861\u20137.","journal-title":"Kidney Int"},{"key":"1700_CR53","first-page":"56","volume":"13","author":"K Matsumoto","year":"2017","unstructured":"Matsumoto K, Ikeda Y, Yamaguchi S, Sanematsu M, Fukuda M, Takashima T, et al. Long-term outcomes of tonsillectomy for IgA nephropathy patients: a retrospective cohort study, two-center analysis with the inverse probability therapy weighting method. Nephrology (Carlton) 2017;13:56.","journal-title":"Nephrology (Carlton)"},{"issue":"8","key":"1700_CR54","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1093\/ndt\/gfu020","volume":"29","author":"T Kawamura","year":"2014","unstructured":"Kawamura T, Yoshimura M, Miyazaki Y, Okamoto H, Kimura K, Hirano K, et al. A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy. Nephrol Dial Transplant. 2014;29(8):1546\u201353.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"1700_CR55","first-page":"147","volume":"51","author":"FM Rasche","year":"1999","unstructured":"Rasche FM, Schwarz A, Keller F. Tonsillectomy does not prevent a progressive course in IgA nephropathy. Clin Nephrol. 1999;51(3):147\u201352.","journal-title":"Clin Nephrol"},{"issue":"1","key":"1700_CR56","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000441852","volume":"132","author":"J Feehally","year":"2016","unstructured":"Feehally J, Coppo R, Troyanov S, Bellur SS, Cattran D, Cook T, et al. Tonsillectomy in a European Cohort of 1147 patients with IgA nephropathy. Nephron. 2016;132(1):15\u201324.","journal-title":"Nephron"},{"issue":"7","key":"1700_CR57","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1093\/ndt\/gfs093","volume":"27","author":"C Ponticelli","year":"2012","unstructured":"Ponticelli C. Tonsillectomy and IgA nephritis. Nephrol Dial Transplant. 2012;27(7):2610\u20133.","journal-title":"Nephrol Dial Transplant"},{"issue":"9156","key":"1700_CR58","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S0140-6736(98)03563-6","volume":"353","author":"C Pozzi","year":"1999","unstructured":"Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999;353(9156):883\u20137.","journal-title":"Lancet"},{"issue":"12","key":"1700_CR59","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1093\/ndt\/gfp356","volume":"24","author":"C Manno","year":"2009","unstructured":"Manno C, Torres DD, Rossini M, Pesce F, Schena FP. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant. 2009;24(12):3694\u2013701.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"1700_CR60","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1053\/j.ajkd.2008.07.029","volume":"53","author":"J Lv","year":"2009","unstructured":"Lv J, Zhang H, Chen Y, Li G, Jiang L, Singh AK, et al. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis. 2009;53(1):26\u201332.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"1700_CR61","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/MNH.0000000000000336","volume":"07","author":"S Barbour","year":"2017","unstructured":"Barbour S, Feehally J. An update on the treatment of IgA nephropathy. Curr Opin Nephrol Hypertens. 2017;07(4):319\u201326. 26(.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"1","key":"1700_CR62","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1681\/ASN.2017060713","volume":"29","author":"T Rauen","year":"2018","unstructured":"Rauen T, Fitzner C, Eitner F, Sommerer C, Zeier M, Otte B, et al. Effects of two immunosuppressive treatment protocols for IgA nephropathy. J Am Soc Nephrol. 2018;29(1):317\u201325.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"1700_CR63","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.semnephrol.2017.05.019","volume":"37","author":"J Feehally","year":"2017","unstructured":"Feehally J. Immunosuppression in IgA nephropathy: guideline medicine versus personalized medicine. Semin Nephrol. 2017;37(5):464\u201377.","journal-title":"Semin Nephrol"},{"issue":"4","key":"1700_CR64","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/ki.2014.63","volume":"86","author":"R Coppo","year":"2014","unstructured":"Coppo R, Troyanov S, Bellur S, Cattran D, Cook HT, Feehally J, et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int. 2014;86(4):828\u201336.","journal-title":"Kidney Int"},{"issue":"1","key":"1700_CR65","doi-asserted-by":"publisher","first-page":"158","DOI":"10.2215\/CJN.10560917","volume":"13","author":"FWK Tam","year":"2018","unstructured":"Tam FWK, Pusey CD. TESTING corticosteroids in IgA nephropathy: a continuing challenge. Clin J Am Soc Nephrol. 2018;13(1):158\u201360.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"1700_CR66","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/ki.2013.210","volume":"84","author":"SJ Barbour","year":"2013","unstructured":"Barbour SJ, Cattran DC, Kim SJ, Levin A, Wald R, Hladunewich MA, et al. Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease. Kidney Int. 2013;84(5):1017\u201324.","journal-title":"Kidney Int"},{"issue":"11","key":"1700_CR67","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1093\/ndt\/gfw286","volume":"11","author":"T Rauen","year":"2016","unstructured":"Rauen T, Eitner F, Fitzner C, Floege J. Con: STOP immunosuppression in IgA nephropathy. Nephrol Dial Transplant. 2016;11(11):1771\u20134","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"1700_CR68","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/ndt\/gfw285","volume":"11","author":"C Pozzi","year":"2016","unstructured":"Pozzi C. Pro. STOP immunosuppression in IgA nephropathy? Nephrol Dial Transplant. 2016;11(11):1766\u201370. 31(.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"1700_CR69","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/08830185.2016.1276903","volume":"36","author":"E Samy","year":"2017","unstructured":"Samy E, Wax S, Huard B, Hess H, Schneider P. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases. Int Rev Immunol. 2017;36(1):3\u201319.","journal-title":"Int Rev Immunol"},{"issue":"11","key":"1700_CR70","doi-asserted-by":"publisher","first-page":"e3099","DOI":"10.1097\/MD.0000000000003099","volume":"95","author":"Y Zhai","year":"2016","unstructured":"Zhai Y, Zhu L, Shi S, Liu L, Lv J, Zhang H. Increased APRIL expression induces IgA1 Aberrant glycosylation in IgA nephropathy. Medicine (Baltimore). 2016;95(11):e3099.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"1700_CR71","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cellimm.2006.08.002","volume":"241","author":"DD McCarthy","year":"2006","unstructured":"McCarthy DD, Chiu S, Gao Y, Summers-deLuca LE, Gommerman JL. BAFF induces a hyper-IgA syndrome in the intestinal lamina propria concomitant with IgA deposition in the kidney independent of LIGHT. Cell Immunol. 2006;241(2):85\u201394.","journal-title":"Cell Immunol"},{"issue":"3","key":"1700_CR72","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.3892\/mmr.2014.2359","volume":"10","author":"W Li","year":"2014","unstructured":"Li W, Peng X, Liu Y, Liu H, Liu F, He L, et al. TLR9 and BAFF: their expression in patients with IgA nephropathy. Mol Med Rep. 2014;10(3):1469\u201374.","journal-title":"Mol Med Rep"},{"issue":"10","key":"1700_CR73","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1172\/JCI45563","volume":"121","author":"DD McCarthy","year":"2011","unstructured":"McCarthy DD, Kujawa J, Wilson C, Papandile A, Poreci U, Porfilio EA, et al. Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy. J Clin Invest. 2011;121(10):3991\u20134002.","journal-title":"J Clin Invest"},{"issue":"11","key":"1700_CR74","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1136\/annrheumdis-2013-205067","volume":"74","author":"D Isenberg","year":"2015","unstructured":"Isenberg D, Gordon C, Licu D, Copt S, Rossi CP, Wofsy D. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis. 2015;74(11):2006\u201315.","journal-title":"Ann Rheum Dis"},{"key":"1700_CR75","doi-asserted-by":"publisher","first-page":"747","DOI":"10.2147\/DDDT.S114552","volume":"11","author":"A Lenert","year":"2017","unstructured":"Lenert A, Niewold TB, Lenert P. Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date. Drug Des Devel Ther. 2017;11:747\u201357.","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"1700_CR76","first-page":"i138","volume":"32","author":"TK Ma","year":"2017","unstructured":"Ma TK, McAdoo SP, Tam FWK. Targeting the tyrosine kinase signalling pathways for treatment of immune-mediated glomerulonephritis: from bench to bedside and beyond. Nephrol Dial Transplant. 2017;32(1):i138.","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"1700_CR77","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.4049\/jimmunol.1102603","volume":"189","author":"MJ Kim","year":"2012","unstructured":"Kim MJ, McDaid JP, McAdoo SP, Barratt J, Molyneux K, Masuda ES, et al. Spleen tyrosine kinase is important in the production of proinflammatory cytokines and cell proliferation in human mesangial cells following stimulation with IgA1 isolated from IgA nephropathy patients. J Immunol. 2012;189(7):3751\u20138.","journal-title":"J Immunol"},{"issue":"1","key":"1700_CR78","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/ki.2015.29","volume":"88","author":"SP McAdoo","year":"2015","unstructured":"McAdoo SP, Bhangal G, Page T, Cook HT, Pusey CD, Tam FWK. Correlation of disease activity in proliferative glomerulonephritis with glomerular spleen tyrosine kinase expression. Kidney Int. 2015;88(1):52\u201360.","journal-title":"Kidney Int"},{"issue":"12","key":"1700_CR79","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1136\/annrheumdis-2014-205361","volume":"74","author":"PC Taylor","year":"2015","unstructured":"Taylor PC, Genovese MC, Greenwood M, Ho M, Nasonov E, Oemar B, et al. OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy. Ann Rheum Dis. 2015;74(12):2123\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1700_CR80","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1681\/ASN.2016060640","volume":"28","author":"RA Lafayette","year":"2017","unstructured":"Lafayette RA, Canetta PA, Rovin BH, Appel GB, Novak J, Nath KA, et al. A randomized, controlled trial of Rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol. 2017;28(4):1306\u201313.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"1700_CR81","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.kint.2017.05.021","volume":"92","author":"J Floege","year":"2017","unstructured":"Floege J. Mucosal corticosteroid therapy of IgA nephropathy. Kidney Int. 2017;92(2):278\u201380.","journal-title":"Kidney Int"},{"key":"1700_CR82","first-page":"A695","volume":"104","author":"S Edsb\u00e4cker","year":"1993","unstructured":"Edsb\u00e4cker S, Wollmer P, Nilsson A, Nillson M. Pharmacokinetics and gastrointestinal transit of budesonide controlled ileal release (CIR) capsules. Gastroenterology. 1993;104:A695.","journal-title":"Gastroenterology"},{"issue":"10084","key":"1700_CR83","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","volume":"389","author":"BC Fellstr\u00f6m","year":"2017","unstructured":"Fellstr\u00f6m BC, Barratt J, Cook H, Coppo R, Feehally J, de Fijter JW, et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet. 2017;389(10084):2117\u201327.","journal-title":"Lancet"},{"issue":"12","key":"1700_CR84","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1681\/ASN.2007050526","volume":"18","author":"HN Reich","year":"2007","unstructured":"Reich HN, Troyanov S, Scholey JW, Cattran DC. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007;18(12):3177\u201383.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"1700_CR85","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1093\/ndt\/gfr527","volume":"27","author":"W Le","year":"2012","unstructured":"Le W, Liang S, Hu Y, Deng K, Bao H, Zeng C, et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transplant. 2012;27(4):1479\u201385.","journal-title":"Nephrol Dial Transplant"},{"issue":"26","key":"1700_CR86","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1056\/NEJMoa030288","volume":"26","author":"PG Richardson","year":"2003","unstructured":"Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;26(26):2609\u201317","journal-title":"N Engl J Med"},{"key":"1700_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-2776(02)80012-8","volume":"80","author":"KL Rock","year":"2002","unstructured":"Rock KL, York IA, Saric T, Goldberg AL. Protein degradation and the generation of MHC class I-presented peptides. Adv Immunol. 2002;80:1\u201370.","journal-title":"Adv Immunol"},{"issue":"11","key":"1700_CR88","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1172\/JCI29832","volume":"116","author":"E Shin","year":"2006","unstructured":"Shin E, Seifert U, Kato T, Rice CM, Feinstone SM, Kloetzel P, et al. Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection. J Clin Invest. 2006;116(11):3006\u201314.","journal-title":"J Clin Invest"},{"issue":"5","key":"1700_CR89","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/ki.2008.579","volume":"75","author":"R Coppo","year":"2009","unstructured":"Coppo R, Camilla R, Alfarano A, Balegno S, Mancuso D, Peruzzi L, et al. Upregulation of the immunoproteasome in peripheral blood mononuclear cells of patients with IgA nephropathy. Kidney Int. 2009;75(5):536\u201341.","journal-title":"Kidney Int"},{"key":"1700_CR90","first-page":"66","volume":"5","author":"R Bahleda","year":"2017","unstructured":"Bahleda R, Le Deley M, Bernard A, Chaturvedi S, Hanley M, Poterie A, et al. Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors. Invest New Drugs. 2017; 5:66","journal-title":"Invest New Drugs"},{"issue":"31","key":"1700_CR91","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1200\/JCO.2017.73.2784","volume":"35","author":"JP Leonard","year":"2017","unstructured":"Leonard JP, Kolibaba KS, Reeves JA, Tulpule A, Flinn IW, Kolevska T, et al. Randomized phase II study of R-CHOP with or without Bortezomib in previously untreated patients with non-germinal center B-cell-like diffuse large B-cell lymphoma. J Clin Oncol. 2017;35(31):3538\u201346.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1700_CR92","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1182\/blood-2017-03-771220","volume":"130","author":"V Sanchorawala","year":"2017","unstructured":"Sanchorawala V, Palladini G, Kukreti V, Zonder JA, Cohen AD, Seldin DC, et al. A phase 1\/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017;130(5):597\u2013605.","journal-title":"Blood"},{"issue":"2","key":"1700_CR93","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1053\/j.ackd.2013.09.004","volume":"21","author":"R Gong","year":"2014","unstructured":"Gong R. Leveraging melanocortin pathways to treat glomerular diseases. Adv Chronic Kidney Dis. 2014;21(2):134\u201351.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"8","key":"1700_CR94","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1681\/ASN.2009101025","volume":"21","author":"A Lindskog","year":"2010","unstructured":"Lindskog A, Ebefors K, Johansson ME, Stef\u00e1nsson B, Granqvist A, Arnadottir M, et al. Melanocortin 1 receptor agonists reduce proteinuria. J Am Soc Nephrol. 2010;21(8):1290\u20138.","journal-title":"J Am Soc Nephrol"},{"key":"1700_CR95","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12882-016-0241-7","volume":"17","author":"A Madan","year":"2016","unstructured":"Madan A, Mijovic-Das S, Stankovic A, Teehan G, Milward AS, Khastgir A. Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series. BMC Nephrol. 2016;17:37.","journal-title":"BMC Nephrol"},{"issue":"1","key":"1700_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40620-015-0245-6","volume":"29","author":"MR Daha","year":"2016","unstructured":"Daha MR, van Kooten C. Role of complement in IgA nephropathy. J Nephrol. 2016;29(1):1\u20134.","journal-title":"J Nephrol"},{"issue":"7","key":"1700_CR97","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1681\/ASN.2014101000","volume":"26","author":"N Maillard","year":"2015","unstructured":"Maillard N, Wyatt RJ, Julian BA, Kiryluk K, Gharavi A, Fremeaux-Bacchi V, et al. Current understanding of the role of complement in IgA nephropathy. J Am Soc Nephrol. 2015;26(7):1503\u201312.","journal-title":"J Am Soc Nephrol"},{"key":"1700_CR98","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1146\/annurev.immunol.23.021704.115835","volume":"23","author":"R Guo","year":"2005","unstructured":"Guo R, Ward PA. Role of C5a in inflammatory responses. Annu Rev Immunol. 2005;23:821\u201352.","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"1700_CR99","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s10875-013-9970-6","volume":"34","author":"L Liu","year":"2014","unstructured":"Liu L, Zhang Y, Duan X, Peng Q, Liu Q, Zhou Y, et al. C3a, C5a renal expression and their receptors are correlated to severity of IgA nephropathy. J Clin Immunol. 2014;34(2):224\u201332.","journal-title":"J Clin Immunol"},{"issue":"3","key":"1700_CR100","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1128\/CMR.4.3.359","volume":"4","author":"JE Figueroa","year":"1991","unstructured":"Figueroa JE, Densen P. Infectious diseases associated with complement deficiencies. Clin Microbiol Rev. 1991;4(3):359\u201395.","journal-title":"Clin Microbiol Rev"},{"issue":"9","key":"1700_CR101","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1681\/ASN.2016111179","volume":"28","author":"DRW Jayne","year":"2017","unstructured":"Jayne DRW, Bruchfeld AN, Harper L, Schaier M, Venning MC, Hamilton P, et al. Randomized trial of C5a receptor inhibitor Avacopan in ANCA-associated vasculitis. J Am Soc Nephrol. 2017;28(9):2756\u201367.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"1700_CR102","first-page":"904","volume":"6","author":"Y Maeng","year":"2013","unstructured":"Maeng Y, Kim M, Park J, Cho C, Oh H, Sung WJ, et al. Glomerular and tubular C4d depositions in IgA nephropathy: relations with histopathology and with albuminuria. Int J Clin Exp Pathol. 2013;6(5):904\u201310.","journal-title":"Int J Clin Exp Pathol"},{"issue":"8","key":"1700_CR103","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1093\/ndt\/13.8.1984","volume":"13","author":"M Endo","year":"1998","unstructured":"Endo M, Ohi H, Ohsawa I, Fujita T, Matsushita M, Fujita T. Glomerular deposition of mannose-binding lectin (MBL) indicates a novel mechanism of complement activation in IgA nephropathy. Nephrol Dial Transplant. 1998;13(8):1984\u201390.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"1700_CR104","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1681\/ASN.2005090923","volume":"17","author":"A Roos","year":"2006","unstructured":"Roos A, Rastaldi MP, Calvaresi N, Oortwijn BD, Schlagwein N, van Gijlswijk-Janssen DJ, et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol. 2006;17(6):1724\u201334.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"1700_CR105","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2353\/ajpath.2008.070131","volume":"172","author":"ME Lamm","year":"2008","unstructured":"Lamm ME, Emancipator SN, Robinson JK, Yamashita M, Fujioka H, Qiu J, et al. Microbial IgA protease removes IgA immune complexes from mouse glomeruli in vivo: potential therapy for IgA nephropathy. Am J Pathol. 2008;172(1):31\u20136.","journal-title":"Am J Pathol"},{"issue":"9","key":"1700_CR106","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1681\/ASN.2015080856","volume":"27","author":"SM Lechner","year":"2016","unstructured":"Lechner SM, Abbad L, Boedec E, Papista C, Le Stang M, Moal C, et al. IgA1 protease treatment reverses mesangial deposits and hematuria in a model of IgA nephropathy. J Am Soc Nephrol. 2016;27(9):2622\u20139.","journal-title":"J Am Soc Nephrol"},{"issue":"7164","key":"1700_CR107","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/nature06244","volume":"449","author":"PJ Turnbaugh","year":"2007","unstructured":"Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The human microbiome project. Nature. 2007;449(7164):804\u201310.","journal-title":"Nature"},{"issue":"6","key":"1700_CR108","doi-asserted-by":"publisher","first-page":"e99006","DOI":"10.1371\/journal.pone.0099006","volume":"9","author":"M Angelis De","year":"2014","unstructured":"De Angelis M, Montemurno E, Piccolo M, Vannini L, Lauriero G, Maranzano V, et al. Microbiota and metabolome associated with immunoglobulin A nephropathy (IgAN). PLoS One. 2014;9(6):e99006.","journal-title":"PLoS One"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-019-01700-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-019-01700-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-019-01700-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T19:39:19Z","timestamp":1581536359000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-019-01700-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,13]]},"references-count":108,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["1700"],"URL":"https:\/\/doi.org\/10.1007\/s10157-019-01700-1","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,13]]},"assertion":[{"value":"17 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Haresh Selvaskandan, Chee Kay Cheung, Masahiro Muto have declared that no conflict of interest exists. Jonathan Barratt: Consultancies: Omeros, EMD Serono, Calliditas, Novartis, Aduro Biotech, Retrophin.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"This article does not contain any studies with human participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}